Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the

Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods incre

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswi

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.22 per share which beat the an

Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution con

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswir

Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78

American and European households may be growing wealthier at a similar pace, but the composition of

Tesla Inc (NASDAQ:TSLA) CEO Elon Musk on Thursday shared an update on the company’s semiconductor pl

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX)

Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined

Financial Outlook: Building Durable Growth and Long–Term ValueProtalix enters 2026 with a profitable

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.06) per share which missed the

Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) appr

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined

Shares in Pennon Group PLC (LSE:PNN, OTC:PEGRY) rose 3.4% to 553.5p on Tueaday morning despite the o

AIM modelling company raises £450,000 at a steep discount, betting that investment in growth will ju

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has appro

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has appro

The US Justice Department has reportedly reached a settlement with Ticketmaster and its parent compa

European Commission approved dosing regimen reduces the burden for eligible patients, their families

This press release is intended for US audiences for transparency relative to global news for the Fab

Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and JATT Acquisition (NYSE: JATT - Get Free R

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examina

Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the discovery, dev

Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–power

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Protalix BioTherapeutics (AMEX:PLX)

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.03 per share which missed the

Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc.

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for it

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it